Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA.
J Biol Chem. 2011 Jun 10;286(23):21002-12. doi: 10.1074/jbc.M110.200139. Epub 2011 Apr 25.
Because of their important function, matrix metalloproteinases (MMPs) are promising drug targets in multiple diseases, including malignancies. The structure of MMPs includes a catalytic domain, a hinge, and a hemopexin domain (PEX), which are followed by a transmembrane and cytoplasmic tail domains or by a glycosylphosphatidylinositol linker in membrane-type MMPs (MT-MMPs). TIMPs-1, -2, -3, and -4 are potent natural regulators of the MMP activity. These are the inhibitory N-terminal and the non-inhibitory C-terminal structural domains in TIMPs. Based on our structural modeling, we hypothesized that steric clashes exist between the non-inhibitory C-terminal domain of TIMPs and the PEX of MMPs. Conversely, a certain mobility of the PEX relative to the catalytic domain is required to avoid these obstacles. Because of its exceedingly poor association constant and, in contrast with TIMP-2, TIMP-1 is inefficient against MT1-MMP. We specifically selected an MT1-MMP·TIMP-1 pair to test our hypothesis, because any improvement of the inhibitory potency would be readily recorded. We characterized the domain-swapped MT1-MMP chimeras in which the PEX of MMP-2 (that forms a complex with TIMP-2) and of MMP-9 (that forms a complex with TIMP-1) replaced the original PEX in the MT1-MMP structure. In contrast with the wild-type MT1-MMP, the diverse proteolytic activities of the swapped-PEX chimeras were then inhibited by both TIMP-1 and TIMP-2. Overall, our studies suggest that the structural parameters of both domains of TIMPs have to be taken into account for their re-engineering to harness the therapeutic in vivo potential of the novel TIMP-based MMP antagonists with constrained selectivity.
由于其重要的功能,基质金属蛋白酶(MMPs)是多种疾病(包括恶性肿瘤)有前途的药物靶点。MMPs 的结构包括催化结构域、铰链和血红蛋白结构域(PEX),其后是跨膜和细胞质尾部结构域或膜型 MMP(MT-MMP)中的糖基磷脂酰肌醇接头。TIMP-1、-2、-3 和 -4 是 MMP 活性的有效天然调节剂。这些是 TIMP 的抑制性 N 端和非抑制性 C 端结构域。基于我们的结构建模,我们假设 TIMP 的非抑制性 C 端结构域与 MMP 的 PEX 之间存在空间冲突。相反,PEX 相对于催化结构域的一定的可移动性是避免这些障碍所必需的。由于其极其差的缔合常数,并且与 TIMP-2 相反,TIMP-1 对 MT1-MMP 的效率不高。我们特别选择了 MT1-MMP·TIMP-1 对来测试我们的假设,因为抑制效力的任何提高都很容易记录下来。我们对结构域交换的 MT1-MMP 嵌合体进行了表征,其中 MMP-2(与 TIMP-2 形成复合物)和 MMP-9(与 TIMP-1 形成复合物)的 PEX 取代了 MT1-MMP 结构中的原始 PEX。与野生型 MT1-MMP 相比,交换 PEX 嵌合体的各种蛋白水解活性随后被 TIMP-1 和 TIMP-2 抑制。总体而言,我们的研究表明,TIMP 两个结构域的结构参数都必须考虑在内,以便对其进行重新设计,以利用新型具有约束选择性的基于 TIMP 的 MMP 拮抗剂的体内治疗潜力。